Overview
NBIX market data
Price History
NBIX price chart · 1M
- O
- 157.70
- H
- 157.96
- L
- 154.94
- C
- 155.61
- Vol
- 59,012.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $157.70
- Previous Close
- $158.28
- Day High
- $157.96
- Day Low
- $154.94
- 52 Week High
- $186.11
- 52 Week Low
- $125.38
- 7 Day Return
- +1.06%
- 30 Day Return
- -3.64%
- 90 Day Return
- -4.64%
- 1 Year Return
- +19.06%
- Daily Notional Volume
- $9.2M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 22.42 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $4.67 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.36 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 20.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $122.14 – $186.12 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $15.8B · P/B 4.35 · P/S 4.69.
Company News
10 captured
Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's CognitionGlobenewswire Inc ·
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Lowers Price Target to $182Benzinga ·